Novartis AG

NVS Healthcare Drug Manufacturers General

Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.

Revenue
+4.67%
EPS
−69.1%
Free cash flow
−17.8%
Total debt
+53.9%

Quarter to September 2026, against a year earlier

162.04 2.94 −1.78%
Market cap
$296.4B
P/E
30.9×
Fwd P/E
23.2×
Dividend yield
2.93%
F-score
8/9
Altman Z
4.13
Beneish M
−2.49
Dividend safety
66/100

Novartis AG (NVS) Book value per share

Alert me on Book value per share

Novartis AG's book value per share at the end of fiscal 2025 was 24.0×, up 9.79% from 21.9× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 19.8×. Over the past ten years it has ranged from 21.9× (fiscal 2024) to 33.9× (fiscal 2018); the current reading is higher than 27% of that period. Novartis AG ranks 8th of 21 Drug Manufacturers General companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 24.0× 9.79%
FY2024 21.9× (2.85%)
FY2023 22.5× (17.39%)
FY2022 27.2× (9.89%)
FY2021 30.2× 21.50%
FY2020 24.9× 2.63%
FY2019 24.2× (28.54%)
FY2018 33.9× 7.25%
FY2017 31.6× 0.30%
FY2016 31.5× (1.72%)

Quarterly newest first

Period Book value per share Change
Sep 2026 19.8× (10.02%)
Jun 2026 22.0× 7.98%
Mar 2026 20.4× (15.06%)
Dec 2025 24.0× 3.32%
43 more quarters

Against its own ten years

Low 21.9× High 33.9×
Ten-year median 27.2×
Current reading's percentile 27

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on NVS